STERIS Corporation Submits New Sterilization System To FDA and Announces Developments on SYSTEM 1 Warn...(creased pressure onpricing that leads to...),Health

Date:1/20/2009

creased pressure on pricing that leads to erosion of profit margins, (b) the possibility that market demand will not develop for new technologies, products or applications, including the new sterilization system referenced here, or the Company's business initiatives will take longer, cost more or produce lower benefits than anticipated, (c) the possibility that application of or compliance with laws, court rulings, regulations, regulatory actions, including without limitation the previously disclosed FDA warning letter, certifications or other requirements or standards may delay or prevent new product introductions, affect the production and marketing of existing products, or otherwise affect Company performance, results, or value, (d) the potential of international unrest or effects of fluctuations in currencies, tax assessments or rates, raw material costs, benefit or retirement plan costs, or other regulatory compliance costs, (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company's products and services, (f) the possibility that financial impact or other outcomes may not be as anticipated, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with the matters described in this release or the conference call referenced here, including the impact on the currently marketed sterilizer or the ability to obtain clearance or market acceptance of the new sterilization system, may adversely impact Company performance, results, or value, (g) the effect of the credit crisis on our ability, as well as the ability of our customers and suppliers, to adequately access the credit markets when needed, and (h) those risks described in our Annual Report on Form 10-K for the year ended March 31, 2008, filed with the SEC on May 30, 2008, under Item 1A, "Risk Factors," and the Quarterly Report on Form 10-Q for the quarter ended September 30, 200
'/>"/>

SOURCE STERIS Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
2. STERIS Corporation Announces Date of Fiscal 2008 Second Quarter Earnings Release and Conference Call
3. STERIS Corporation Announces Fiscal 2008 Second Quarter Results
4. STERIS Corporation Announces Date of Fiscal 2008 Third Quarter Earnings Release and Conference Call
5. STERIS Corporation Declares Regular Quarterly Dividend
6. STERIS Corporation Announces Fiscal 2008 Third Quarter Results
7. STERIS Corporation Promotes Timothy L. Chapman to Group President of Healthcare
8. STERIS Corporation Announces New $300 Million Share Repurchase Authorization
9. STERIS Corporation Names Michael J. Tokich Chief Financial Officer
10. STERIS Corporation Declares Regular Quarterly Dividend
11. Steris Corporation Announces the Appointment of Two New Directors